Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.